Treatment Failure Resulting from Resistance of Staphylococcus aureus to Daptomycin
Year: 2006
Type: article
Study design: Case Report
Abstract: Daptomycin, a new cyclic lipopeptide, was recently approved for the treatment of infections by gram-positive organisms, including infections with methicillin-resistant Staphylococcus aureus (MRSA). A patient infected with infected with MRSA developed resistance to daptomycin after prolonged exposure, which resulted in clinical failure. Clinicians should be aware of the possibility of daptomycin resistance and should consider routine testing for daptomycin susceptibility.
Source: Journal of Clinical Microbiology
Author: Daniel J. Skiest
Institution: The University of Texas Southwestern Medical Center
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W2139101850